MSD Escapes Action By UK Competition Body Over Remicade Discount Scheme
Executive Summary
The UK Competition and Markets Authority has announced that there are “no grounds for action” against MSD in relation to a discount scheme the company introduced in England to fend off biosimilar competition for Remicade. But the competition watchdog had some words of warning for other companies considering discount schemes designed to protect a dominant market position.